News & Updates
Filter by Specialty:
AI improves physician accuracy in identifying prostate cancer extent
Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.
AI improves physician accuracy in identifying prostate cancer extent
16 Aug 2024
![[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial](https://sitmspst.blob.core.windows.net/images/articles/hk-pfi-842mo00-32d2c2af-d35d-4e81-8fd4-c4292f4a20a6-square.png)
[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial
American Society of Clinical Oncology (ASCO) 2024: 5-year data from the international, randomized, open-label phase III CROWN trial comparing lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small-cell lung cancer (NSCLC) demonstrate unprecedented progression-free survival (PFS) with lorlatinib.
[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial
16 Aug 2024
Adjunctive brexpiprazole benefits seen in Asian adults with MDD in real-world
Up to 3 months of treatment with adjunctive brexpiprazole helps with symptom severity in Asian adults with major depressive disorder (MDD) and inadequate response to antidepressants in a real-life clinical setting in Singapore.